Table 1.

BET inhibitors in clinical trials, from ClinicalTrials.gov (https://clinicaltrials.gov/), last accessed on September 10, 2017

Drug (administration)ClinicalTrials.gov # (start date)PhaseTumor typeStatusResults
GSK525762 (oral)NCT01587703 (March 2012)ISolid tumors, NUT carcinomaOngoing/recruiting patientsAbstract (67)
NCT01943851 (May 2014)IHematologic malignanciesOngoing/recruiting patientsNot reported
NCT02706535 (May 2016)IAdvanced malignancies, effects of itraconazole and rifampicin on the pharmacokinetics of GSK525762CompletedNot reported
NCT03150056 (May 2017)IProstate cancer, in combination with androgen deprivationOngoing/recruiting patientsNot reported
NCT02964507 (February 2017)IIEstrogen receptor–positive breast cancer, in combination with fulvestrantOngoing/recruiting patientsNot reported
OTX015/MK-8628 (oral)NCT01713582 (December 2012)IHematologic malignanciesCompletedReported (60, 61)
NCT02259114 (October 2014)ISolid tumorsCompletedAbstract (65)
NCT02296476 (October 2014)IGlioblastomaTerminatedAbstract (69)
NCT02698176 (May 2016)ISolid tumorsTerminatedNot reported
CPI-0610 (oral)NCT01949883 (September 2013)INon-Hodgkin lymphomasOngoing/recruiting patientsAbstract (62)
NCT02157636 (July 2014)IMultiple myelomaOngoing/recruiting patientsNot reported
NCT02158858 (June 2014)IMyelodysplastic syndrome, leukemiaOngoing/recruiting patientsNot reported
RO6870810/TEN-010 (subcutaneous injection)NCT01987362 (October 2013)ISolid tumorsOngoing/not recruiting patientsAbstract (66)
NCT02308761 (November 2014)IMyelodysplastic syndrome, leukemiaOngoing/recruiting patientsNot reported
NCT03068351 (June 2017)IMultiple myeloma, single agent and in combination with daratumumabOngoing/recruiting patientsNot reported
NCT03255096 (August 2017)ILymphomas, in combination with venetoclax and rituximabOngoing/recruiting patientsNot reported
BAY1238097 (oral)NCT02369029 (February 2015)ISolid tumors, non-Hodgkin lymphomasTerminatedAbstract (70)
GS-5829 (oral)NCT02392611 (March 2015)ISolid tumors and lymphomas; expansion cohort in breast cancer in combination with exemestane or fulvestrantOngoing/not recruiting patientsNot reported
NCT02607228 (December 2015)I/IIProstate cancer, single agent and in combination with enzalutamideOngoing/recruiting patientsNot reported
NCT02983604(January 2017)I/IIBreast cancer, in combination with exemestane or fulvestarantOngoing/recruiting patientsNot reported
ABBV-075 (oral)NCT02391480 (April 2015)ISolid tumors and hematologic malignancies; expansion cohorts in combination with venetoclaxOngoing/recruiting patientsNot reported
FT-1101 (oral)NCT02543879 (September 2015)IHematologic malignanciesOngoing/recruiting patientsNot reported
INCB054329 (oral)NCT02431260 (May 2015)I/IISolid tumors, non-Hodgkin lymphomas, acute leukemia, chronic myeloid leukemia, multiple myelomaOngoing/not recruiting patientsNot reported
BMS-986158 (oral)NCT02419417 (June 2015)I/IISolid tumorsOngoing/recruiting patientsNot reported
BI 894999 (oral)NCT02516553 (July 2015)ISolid tumors, non-Hodgkin lymphomasOngoing/not recruiting patientsNot reported
N-methyl pyrrolidone (oral)NCT02468687 (August 2015)IMultiple myelomaOngoing/recruiting patientsNot reported
PLX51107 (oral)NCT02683395 (March 2016)ISolid tumors, hematologic malignanciesOngoing/recruiting patientsNot reported
GSK2820151 (oral)NCT02630251 (April 2016)ISolid tumorsOngoing/recruiting patientsNot reported
ZEN-3694 (oral)NCT02705469 (April 2016)IProstate cancerOngoing/recruiting patientsNot reported
NCT02711956 (December 2016)IProstate cancer, in combination with enzalutamideOngoing/not recruiting patientsNot reported
INCB057643 (oral)CT02711137 (May 2016)I/IISolid tumors, hematologic malignanciesOngoing/recruiting patientsNot reported
ODM-207 (oral)NCT03035591 (December 2016)I/IISolid tumorsOngoing/recruiting patientsNot reported